ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AVCT Avacta Group Plc

41.00
-0.25 (-0.61%)
07 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -0.61% 41.00 40.50 41.50 41.25 40.75 41.25 1,583,505 16:28:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -2.97 116.28M
Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 41.25p. Over the last year, Avacta shares have traded in a share price range of 40.40p to 166.50p.

Avacta currently has 283,614,110 shares in issue. The market capitalisation of Avacta is £116.28 million. Avacta has a price to earnings ratio (PE ratio) of -2.97.

Avacta Share Discussion Threads

Showing 79101 to 79124 of 80075 messages
Chat Pages: Latest  3167  3166  3165  3164  3163  3162  3161  3160  3159  3158  3157  3156  Older
DateSubjectAuthorDiscuss
22/2/2024
10:22
Vertiz ...yup, could be the fluffer rns for sure.
amanitaangelicus
22/2/2024
10:22
Time needed to evaluate latest data? I doubt it bud. Quick as ... no Smiths trying to use the already well analysed data to tempt a seller. Probably failed. Now the convi boys are demanding their pound of flesh once more. Fear not, convis have never been an issue. Why not. Tickboo said so!
amanitaangelicus
22/2/2024
10:14
And as Avacta is due an update on the value of its JV with Daewoo....Affyxell this seems pertinent.....from alextak LSE:

It seems that Affyxell is recruiting not one employee but several employees.☀5039;

vertizeasun
22/2/2024
10:09
Exactly fieldhouse....and this from gmcc on LSE:

"Guess LD might remain Avacta asset at least for the time being :





"21 FEBRUARY 2024

Launch Diagnostics will be moving from its current office at Ash House, Ash Road, New Ash Green, Longfield, Kent to new premises.

From Monday 26th February 2024 our new office address will be:

Launch Diagnostics Limited, Lakeview West, Crossways Business Park, Galleon Boulevard, Dartford, Kent DA2 6QE

Please note, our telephone numbers will remain the same.

In addition, the Warehouse and Technical Department will still be located at its current location, so there will be no change to our delivery/despatch address

Unit 11, West Yoke Farm, Michaels Lane, Ash, New Ash Green, Sevenoaks TN15 7EP"

vertizeasun
22/2/2024
10:03
The expectations of many that the new company deal maker can come up with substantial new investors in just a few weeks is wishful thinking !

I would say you are talking months and not weeks.
In the mean time enough cash to go until late year end . Cutting it fine ,yes ,but not out of the ordinary. Time needed to evaluate the latest data .

fieldhouse
22/2/2024
09:54
So, the share price drops to 50p. £30 million raised to take through phase 2.
Uncertainty goes and dose escalation progresses well with good data from C7.
Two weekly dosing progresses in the US.

Worries all gone ---- Share price and company do have a paradigm shift.

A lot of money in the mean time transferred to the soothsayer's

QED

fieldhouse
22/2/2024
09:39
Tickboo et al have left the building. I think Whitey has lost a wodge too. Only Chesh in profit now.
amanitaangelicus
22/2/2024
09:36
Funny you should remember something like that today
inaminute
22/2/2024
09:21
Seem to recall Tom, back in the day, valuing this thing at 25p, but agreeing that a placing around the 50p mark was possible
sandcrab2
22/2/2024
09:14
Smith clearly cant get a licensing partner. Reset convis and some new ones inbound Supported by volume today. It s a rat trap Billy, and you.ve been caught. 35p all but nailed on. Myles, Tickboo TimeLord ,we need your help!
amanitaangelicus
22/2/2024
08:25
Could see 35-40p at this rate! Graph looks ugly. Come on TimeLord Smith get that tardis taken to Halfords or Orange County Choppers for an overhaul! The daleks are upon us ( convi metaphor) Hopin the Cybermen dont join the fun!
amanitaangelicus
22/2/2024
07:57
Ohwhatfun ...please stop. Mkt cap is definitely high for where we are,granted. But, with a decent back wind, if the data, even anecdotally, is as good as Time Lord Smith suggests, then a successful Ph2 will make the current mkt cap look farcical. The mkt has this possibility in the mkt cap, DCFs calcs etc.So,1/ Licensing deal ...okay. Has its price but Smith has managed to persuade a decent pharma that he.s onto something2/ Convi reset ...Smith all hot air ...anecdotal data on efficacy just doesnt hold up.3/ Smith.s done such a good job, data looks so good, a T/O is accepted. Smith makes a fortune,has a seat on the company, big salary, pension, options, job s a gd un.Ps if Phase 2 fails efficacy challenge, forget the pipeline.Now, where s that fluffer rns? Where.s Myles? Too silent, way too silent.Enjoy your day.
amanitaangelicus
21/2/2024
17:36
As you well know, if it hovers at mid 80’s the market turns the screw on deal day, in the morning session then discounts from there, done on a fluid price if the begging bowl is out. Thus, at this point 60-70p more likely, but still in reality a crazy market cap compared to small companies as a whole.

50p and below isn’t a crazy thought given the trend.

Even then it’s a market cap of £150m plus including the added shares dilution.

I don’t wish it, it’s just happens to be typical market behaviour. It’s well known that trying to get funding in recent times can result in large discounts.

For the chart gurus, it’s looking grim, old floor levels have caved in.

ohwhatfun
21/2/2024
17:28
Daft pi.s just sitting on their shares, blissfully unaware of the TA angles and share price moves. Convi re-set looking inevitable ...existing ii.s pished off no doubt. Drip selling perhaps. Did post likely share price drop to points - it's happening. Oh well ...where the heck is Time Lord Smith? Puffing away on a big fat Havanna thinking this is the life ...
amanitaangelicus
21/2/2024
16:58
88p close. Going to raise at 75p if they are lucky now. Given the price action I guess they are struggling to generate interest

Must be very difficult when you look what is going on at FARN when they ran out of cash for their trial.

loglorry1
21/2/2024
15:57
Growing health care......share price says otherwise
kpe
21/2/2024
14:43
Money moving to APH [LSE] , excellent growing health care company
blackhorse23
21/2/2024
14:39
Yes, but there are schemes you know!!!!!!
atmysignal
21/2/2024
13:42
And don't come back here moaning !!

Stop your bed wetting !!

fieldhouse
21/2/2024
13:40
If you are not happy with your investment -- Just sell up --simple!!

A salary of £444,000 would attract a tax bill of £246352 .

fieldhouse
21/2/2024
13:03
What about the other new starters, on 250k plus per yearGissa job avct!
atmysignal
21/2/2024
12:57
£444,000k ish year. And je sold shares during covid for a new house/ extension(?) Makes you wonder. Loadsa money ...plus share options ...swimming in it.
amanitaangelicus
21/2/2024
12:44
Management are on such astronomical salaries, and I mean ASTRONOMICAL, that they don't care too much about their share price as some management actually get paid 10's of thousands per month, yes, you read that correctly, PER MONTH, clear of tax.Let that sink in.So whether the stock is 100p, 90p or 70p makes not much difference to management if you have that sort of money hitting your bank account each month.
atmysignal
21/2/2024
10:57
Hi Raj ...good man. The ' reset ' point was totally missed by most here - they just dont understand convis. No chance of a normal placing on top of a convi ...most unlikely. Another convi placing on top of existing? Very likely if Time Lord Smith cant get a decent licensing deal. Think Dragons Den and ' give up'. Bound to be some pain in the licensing despite Tickboo blabbering on about non- dilutive finance. No such thing as a free lunch - never is in the City.Phase 1 basic mtd stuff. Ph2 efficacy - massive. Will be lots of anecdotal stuff- there always,always is. It.s not that this is unimportant but rather there.s no real double blind quality stuff surrounding it. There isnt ,so dont try and argue. Synairgen was a classic example or trial design issues, cohort issues during covid. USA boys saw straight through the carp and killed it. Plus, the yanks dont like non US companies. Politics everywhere in the bent USA. We just have to wait. Best outcome? Take out at 120p. Tk the money and run. Mkt cap unsustainable at its current level. The 2 sales outlet purchases, what.s dropping to the bottom line - has Smith been shafted? Let.s see.GLA.
amanitaangelicus
Chat Pages: Latest  3167  3166  3165  3164  3163  3162  3161  3160  3159  3158  3157  3156  Older